Kang‐Yi Su

3.9k total citations · 1 hit paper
82 papers, 2.4k citations indexed

About

Kang‐Yi Su is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kang‐Yi Su has authored 82 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 30 papers in Molecular Biology. Recurrent topics in Kang‐Yi Su's work include Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (15 papers) and Cancer Genomics and Diagnostics (12 papers). Kang‐Yi Su is often cited by papers focused on Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (15 papers) and Cancer Genomics and Diagnostics (12 papers). Kang‐Yi Su collaborates with scholars based in Taiwan, United States and United Kingdom. Kang‐Yi Su's co-authors include Sung‐Liang Yu, Pan‐Chyr Yang, Gee‐Chen Chang, Jin‐Yuan Shih, James Chih‐Hsin Yang, Bing‐Ching Ho, Jeremy J.W. Chen, Hsuan‐Yu Chen, Wing‐Kai Chan and Ker-Chau Li and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and PLoS ONE.

In The Last Decade

Kang‐Yi Su

75 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

2012 429 citations Kang‐Yi Su, Hsuan‐Yu Chen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kang‐Yi Su Taiwan	26	1.2k	1.1k	894	606	141	82	2.4k
Yuanbin Chen China	30	687 0.6×	796 0.7×	1.3k 1.5×	805 1.3×	66 0.5×	92	2.8k
Dong Hu Australia	27	288 0.2×	508 0.5×	1.3k 1.5×	467 0.8×	116 0.8×	78	2.2k
Shuichi Fujioka Japan	27	447 0.4×	829 0.8×	1.4k 1.5×	606 1.0×	133 0.9×	81	2.8k
Mudher Albassam United States	17	653 0.5×	769 0.7×	583 0.7×	183 0.3×	97 0.7×	43	1.7k
Liang‐Chuan Lai Taiwan	30	343 0.3×	386 0.4×	2.4k 2.6×	1.0k 1.7×	126 0.9×	146	3.4k
Qi Yang China	35	463 0.4×	739 0.7×	2.1k 2.4×	990 1.6×	306 2.2×	161	3.5k
Xiaoping Chen China	31	314 0.3×	553 0.5×	1.6k 1.8×	770 1.3×	224 1.6×	124	2.9k
Jiao Liu China	30	1.1k 0.9×	461 0.4×	2.3k 2.6×	1.1k 1.8×	111 0.8×	124	3.6k
Michael Ladomery United Kingdom	34	353 0.3×	307 0.3×	2.9k 3.2×	721 1.2×	202 1.4×	74	3.6k
Yongxiang Li China	22	269 0.2×	469 0.4×	1.1k 1.2×	570 0.9×	272 1.9×	118	2.0k

Countries citing papers authored by Kang‐Yi Su

Since Specialization

Citations

This map shows the geographic impact of Kang‐Yi Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kang‐Yi Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kang‐Yi Su more than expected).

Fields of papers citing papers by Kang‐Yi Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kang‐Yi Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kang‐Yi Su. The network helps show where Kang‐Yi Su may publish in the future.

Co-authorship network of co-authors of Kang‐Yi Su

This figure shows the co-authorship network connecting the top 25 collaborators of Kang‐Yi Su. A scholar is included among the top collaborators of Kang‐Yi Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kang‐Yi Su. Kang‐Yi Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Su, Kang‐Yi, et al.. (2025). PPARγ-Axl axis ameliorates intervertebral disc degeneration by activating PI3K/AKT-mediated autophagy to suppress ferroptosis. Cellular & Molecular Biology Letters. 30(1). 128–128.

Lin, Chia‐I, Yuwen Wang, Kang‐Yi Su, & Ya‐Hui Chuang. (2024). Interleukin-37 exacerbates liver inflammation and promotes IFN-γ production in NK cells. International Immunopharmacology. 142(Pt A). 113086–113086. 4 indexed citations

Tsai, Tzu‐Hsiu, Chien‐Hung Gow, Meng‐Feng Tsai, et al.. (2023). MiR‐503 pleiotropically regulates epithelial‐mesenchymal transition and targets PTK7 to control lung cancer metastasis. Cancer Medicine. 12(13). 14511–14525. 6 indexed citations

Chen, Wei-Ming, et al.. (2023). High-fat diet induces C-reactive protein secretion, promoting lung adenocarcinoma via immune microenvironment modulation. Disease Models & Mechanisms. 16(11). 2 indexed citations

Wu, Jui-Ching, Weijia Luo, Sung‐Liang Yu, et al.. (2023). LCRMP-1 is required for spermatogenesis and stabilises spermatid F-actin organization via the PI3K-Akt pathway. Communications Biology. 6(1). 389–389. 4 indexed citations

Chang, Wen‐Hsin, Yi‐Ju Chen, Kang‐Yi Su, et al.. (2022). Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma. Journal of Proteome Research. 22(4). 1056–1070. 8 indexed citations

Su, Kang‐Yi, Ming-Hsi Sun, Kun‐Chieh Chen, et al.. (2022). Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid. Cancers. 14(12). 2824–2824. 1 indexed citations

Tseng, Jeng‐Sen, Kuo-Hsuan Hsu, Tsung‐Ying Yang, et al.. (2020). Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment. Oncology. 99(1). 32–40. 9 indexed citations

Lee, Chien‐Chang, Ye Liu, Chen Wei, et al.. (2020). Comparison of influenza hospitalization outcomes among adults, older adults, and octogenarians: a US national population-based study. Clinical Microbiology and Infection. 27(3). 435–442. 5 indexed citations

10.

Su, Kang‐Yi, Jeng‐Sen Tseng, Tsung‐Ying Yang, et al.. (2018). Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma. PLoS ONE. 13(11). e0207001–e0207001. 20 indexed citations

11.

Chang, Gee‐Chen, Yi‐Ju Chen, Yi‐Chiung Hsu, et al.. (2017). FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression. Clinical Cancer Research. 24(4). 916–926. 26 indexed citations

12.

Su, Kang‐Yi, Bo‐Shiun Yan, Hao‐Chieh Chiu, et al.. (2017). Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS. Scientific Reports. 7(1). 41486–41486. 21 indexed citations

13.

Molina‐Vila, Miguel Ángel, Sheng‐Yuan Ruan, Kang‐Yi Su, et al.. (2016). Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 94. 46–53. 57 indexed citations

14.

Huang, Kuo‐Yen, Shih-Han Kao, Chi‐Yuan Chen, et al.. (2015). Small Molecule T315 Promotes Casitas B-Lineage Lymphoma–Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation. American Journal of Respiratory and Critical Care Medicine. 193(7). 753–766. 18 indexed citations

15.

Wang, Chi-Chung, Kang‐Yi Su, Hsuan‐Yu Chen, et al.. (2015). HOXA5 Inhibits Metastasis via Regulating Cytoskeletal Remodelling and Associates with Prolonged Survival in Non-Small-Cell Lung Carcinoma. PLoS ONE. 10(4). e0124191–e0124191. 40 indexed citations

16.

Chen, Chun-Chieh, Hsuan‐Yu Chen, Kang‐Yi Su, et al.. (2014). Shisa3 is Associated with Prolonged Survival Through Promoting β-Catenin Degradation in Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 190(4). 433–444. 33 indexed citations

17.

Tseng, Jeng‐Sen, Chih‐Liang Wang, Ming‐Shyan Huang, et al.. (2014). Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. PLoS ONE. 9(9). e107160–e107160. 11 indexed citations

18.

Su, Kang‐Yi, Chao Yu, Yuewen Chen, et al.. (2014). Rutin, a Flavonoid and Principal Component of Saussurea Involucrata, Attenuates Physical Fatigue in a Forced Swimming Mouse Model. International Journal of Medical Sciences. 11(5). 528–537. 72 indexed citations

19.

Su, Kang‐Yi, Hsuan‐Yu Chen, Ker-Chau Li, et al.. (2012). Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(4). 433–440. 429 indexed citations breakdown →

20.

Tsai, Meng-Feng, Kang‐Yi Su, Sung‐Liang Yu, et al.. (2010). Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. American Journal of Respiratory and Critical Care Medicine. 183(8). 1071–1079. 146 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact